Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...
Yahoo! Finance: News·6h ago
More News
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price
Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat·13d ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
Dianthus Therapeutics (DNTH) to Release Earnings on Monday
Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...
MarketBeat·14d ago
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling...
MarketBeat·19d ago
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share...
Nasdaq News: Markets·29d ago
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recomm...
MarketBeat·1mo ago
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High - Still a Buy...
MarketBeat·1mo ago
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH
SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities...